New scan spots hidden prostate cancer that standard tests miss

NCT ID NCT06062745

First seen Nov 06, 2025 · Last updated May 13, 2026 · Updated 21 times

Summary

This study tests whether a special PET scan using 18F-fluciclovine can better detect advanced prostate cancer that doesn't show up well on standard scans. It involves 30 people with metastatic prostate cancer that either has low PSMA levels or neuroendocrine features. Participants get one PET scan and two blood draws to see how well the scan finds cancer lesions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Womens Hospital

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.